In a phase 1/2 study of 86 patients with R/R ALL who underwent CD19 CAR-T-cell therapy, the results demonstrated that persistent severe cytopenia was highly associated with a poor 1-year OS. Here, CD19 is linked to acute lymphoblastic leukemia.